Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

Recombinant C5 (Eculizumab Biosimilar) antibody

Reactivity: Human FACS, in vivo Host: Mouse Monoclonal unconjugated Recombinant Antibody
Catalog No. ABIN7200672
  • Target See all C5 (Eculizumab Biosimilar) products
    C5 (Eculizumab Biosimilar)
    Antibody Type
    Recombinant Antibody
    Reactivity
    Human
    Host
    • 1
    Mouse
    Clonality
    • 1
    Monoclonal
    Conjugate
    • 1
    This C5 (Eculizumab Biosimilar) antibody is un-conjugated
    Application
    Flow Cytometry (FACS), In vivo Studies (in vivo)
    Purpose
    Eculizumab Biosimilar, Human C5 Monoclonal Antibody
    Specificity
    The monoclonal antibody Eculizumab biosimilar specifically binds to the human C5, the terminal complement component 5.
    Characteristics
    Recombinant Humanized IgG2 Monoclonal Antibody.
    Purification
    Protein A affinity column
    Purity
    > 95% by SDS-PAGE under reducing conditions and HPLC.
    Sterility
    0.2 μm filtered
    Endotoxin Level
    < 1 EU per 1 mg of the protein by the LAL method.
    Immunogen
    The monoclonal antibody Eculizumab biosimilar was produced in the Eculizumab biosimilar CHO stable cell line.
    Isotype
    IgG2, IgG4, kappa
  • Application Notes
    ELISA, functional assays such as bioanalytical PK and ADA assays.
    Restrictions
    For Research Use only
  • Format
    Liquid
    Concentration
    1 mg/mL
    Buffer
    PBS, pH 7.4, no stabilizers or preservatives.
    Preservative
    Without preservative
    Handling Advice
    Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
    Storage
    -20 °C
    Storage Comment
    12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
    Expiry Date
    12 months
  • Target
    C5 (Eculizumab Biosimilar)
    Abstract
    C5 (Eculizumab Biosimilar) Products
    Synonyms
    C5a antibody, C5b antibody, CPAMD4 antibody, complement C5 antibody, C5 antibody
    Target Type
    Biosimilar
    Background
    Eculizumab, a recombinant humanized anti-C5 (the terminal Complement component 5) monoclonal antibody, selectively targets and inhibits the terminal portion of the complement cascade. Eculizumab is a first-in-class terminal complement inhibitor to treat paroxysmal nocturnal hemoglobinuria (PNH) with excessive destruction of red blood cells (hemolysis). Eculizumab is also the first agent to treat atypical hemolytic uremic syndrome (aHUS) with abnormal blood clots to form in small blood vessels throughout the body, leading to kidney failure, damage to other vital organs and premature death.

    The complement immune system destroys and removes foreign particles by the complement cascade triggered by foreign particles. The complement proteins activiated in order create holes or pores in the invading organisms, leading to their destruction. The complement immune system in patients can also destroy healthy cells and tissue, resulting in excessive destruction of red blood cells (hemolysis) or abnormal blood clots to form in small blood vessels throughout the body.

    When activated, C5 at a late stage in the complement cascade is involved in activating host cells, thereby attracting pro-inflammatory immune cells, while also destroying cells by triggering pore formation. Eculizumab specifically binds to C5 and inhibits the cleavage of C5 to C5a (a potent anaphylatoxin with prothrombotic and proinflammatory properties) and C5b by the C5 convertase, preventing the generation of the terminal complement complex C5b-9 (which also has prothrombotic and proinflammatory effects). Both C5a and C5b-9 cause the terminal complement-mediated events that are characteristic of PNH and aHUS. By doing so, the normal, disease-preventing functions of proximal complement system are largely preserved, while the properties of C5 that promote inflammation and cell destruction are impeded.
You are here:
Support